Canada’s Drug Agency (CDA-AMC)
In December 2023, it was announced that Canada’s Drug Agency would be built from CADTH. The work of the drug agency expands on CADTH’s existing mandate and functions — which spans drugs, medical devices, and clinical interventions — and includes new work streams such as:
- improving the appropriate prescribing and use of medications
- increasing pan-Canadian data collection and expanding access to drug and treatment data, including real-world evidence data
- reducing drug system duplication and lack of coordination
CADTH adopted the new name Canada’s Drug Agency (CDA-AMC) as of May 1, 2024. An official launch will occur later this year.
New Members Join the Alliance
The CCRA is pleased to announce the addition of two new member organizations: Bladder Cancer Canada and Myeloma Canada, and we welcome new representatives: Michelle Colero, Executive Director, Bladder Cancer Canada and Martine Elias, Executive Director, Myeloma Canada.
... Read More »
The CCRA is pleased to announce the addition of two new member organizations: Bladder Cancer Canada and Myeloma Canada, and we welcome new representatives: Michelle Colero, Executive Director, Bladder Cancer Canada and Martine Elias, Executive Director, Myeloma Canada.
... Read More »
Are you a cancer patient, survivor, or caregiver who is interested in learning more about cancer research?
CCRA’s Patient Involvement in Cancer Research Program (known as PIP) will be offered virtually in the fall of 2021. This program is designed for cancer patients, survivors, and caregivers with an interest in learning more about cancer research and how they can contribute to the re... Read More »
CCRA’s Patient Involvement in Cancer Research Program (known as PIP) will be offered virtually in the fall of 2021. This program is designed for cancer patients, survivors, and caregivers with an interest in learning more about cancer research and how they can contribute to the re... Read More »